1-866-598-7166

Testing Immunotherapy Plus Chemotherapy in Urothelial Carcinoma of the Renal Pelvis

Trial ID: NCT03682068
Kidney Cancer Type: Urothelial carcinoma of the renal pelvis


Background:

Urothelial carcinoma is the most common type of bladder cancer, but it can also start in other parts of the urinary system such as the kidney pelvis, ureter, or urethra. When the cancer has spread or cannot be removed by surgery, chemotherapy is usually the first treatment.

This study is testing whether adding new immune-based treatments—durvalumab (an immunotherapy drug) and tremelimumab (another immunotherapy that works in a slightly different way)—to standard chemotherapy can help patients live longer or keep their cancer under control for a longer time compared to chemotherapy alone.

Durvalumab helps the immune system recognize and attack cancer cells by blocking a “shield” used by the cancer (called PD-L1). 

Tremelimumab targets a different pathway (called CTLA-4) to further activate immune cells. 

Researchers believe that combining these drugs with chemotherapy may make the treatment more effective than chemotherapy alone.


The Trial:

The trial is testing whether adding immunotherapy drugs (durvalumab ± tremelimumab) to standard chemotherapy can help patients live longer or keep their cancer from growing compared to chemotherapy alone.

Participants will be randomly assigned to one of the following treatment groups:

  • Chemotherapy Alone (standard treatment)
  • Durvalumab ± Tremelimumab + Chemotherapy

The trial is not “blind,” meaning both you and your doctor will know which treatment you are receiving.


Basic Eligibility:

  • Must have confirmed urothelial cell carcinoma of the renal pelvis
  • Must not have received chemotherapy
  • Must have had at least one tumor that has not been treated with radiation

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreArthur J.E. Child Comprehensive Cancer Centre Principal InvestigatorNot Given LocationCalgary, AB Trial StatusActive, not recruiting
Hospital / Cancer CentreCross Cancer Institute Principal InvestigatorNot Given LocationEdmonton, AB Trial StatusActive, not recruiting
Hospital / Cancer CentreBC Cancer Principal InvestigatorNot Given LocationVancouver, BC Trial StatusActive, not recruiting
Hospital / Cancer CentreJuravinski Cancer Centre Principal InvestigatorNot Given LocationHamilton, ON Trial StatusActive, not recruiting
Hospital / Cancer CentreThe Ottawa Hospital Principal InvestigatorNot Given LocationOttawa, ON Trial StatusActive, not recruiting
Hospital / Cancer CentreMount Sinai Hospital Principal InvestigatorNot Given LocationToronto, ON Trial StatusActive, not recruiting
Hospital / Cancer CentreJewish General Hospital Principal InvestigatorNot Given LocationMontreal, QC Trial StatusActive, not recruiting
Kidney Cancer Canada